Compared with single-system (SS) disease, MS involvement is associated with higher cytokine/chemokine levels–such as soluble interleukin-2 receptor (sIL-2R) and interleukin-18 (IL-18)–at baseline [14]. This evidence concerns the gene IL18 and myeloid sarcoma.